CoChat

Soluble TREM2 is elevated in Parkinson’s disease subgroups with increased CSF tau

Open access
Wilson, Edward N, Swarovski, Michelle S, Linortner, Patricia, Shahid, Marian, Zuckerman, Abigail J, Wang, Qian, Channappa, Divya, Minhas, Paras S, Mhatre, Siddhita D, Plowey, Edward D, Quinn, Joseph F, Zabetian, Cyrus P, Tian, Lu, Longo, Frank M, Cholerton, Brenna, Montine, Thomas J, Poston, Kathleen L, Andreasson, Katrin I · 2020 · Brain
Cited by 99

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Abstract

Parkinson’s disease is the second most common neurodegenerative disease after Alzheimer’s disease and affects 1% of the population above 60 years old. Although Parkinson’s disease commonly manifests with motor symptoms, a majority of patients with Parkinson’s disease subsequently develop cognitive impairment, which often progresses to dementia, a major cause of morbidity and disability. Parkinson’s disease is characterized by α-synuclein accumulation that frequently associates with amyloid-β and tau fibrils, the hallmarks of Alzheimer’s disease neuropathological changes; this co-occurrence suggests that onset of cognitive decline in Parkinson’s disease may be associated with appearance of pathological amyloid-β and/or tau. Recent studies have highlighted the appearance of the soluble form of the triggering receptor expressed on myeloid cells 2 (sTREM2) receptor in CSF during development of Alzheimer’s disease. Given the known association of microglial activation with advancing Parkinson’s disease, we investigated whether CSF and/or plasma sTREM2 differed between CSF biomarker-defined Parkinson’s disease participant subgroups. In this cross-sectional study, we examined 165 participants consisting of 17 cognitively normal elderly subjects, 45 patients with Parkinson’s disease with no cognitive impairment, 86 with mild cognitive impairment, and 17 with dementia. Stratification of subjects by CSF amyloid-β and tau levels revealed that CSF sTREM2 concentrations were elevated in Parkinson’s disease subgroups with a positive tau CSF biomarker signature, but not in Parkinson’s disease subgroups with a positive CSF amyloid-β biomarker signature. These findings indicate that CSF sTREM2 could serve as a surrogate immune biomarker of neuronal injury in Parkinson’s disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/brain/awaa021

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 99

Metadata

Authors
Wilson, E. N., Swarovski, M. S., Linortner, P., Shahid, M., Zuckerman, A. J., Wang, Q., Channappa, D., Minhas, P. S., Mhatre, S. D., Plowey, E. D., Quinn, J. F., Zabetian, C. P., Tian, L., Longo, F. M., Cholerton, B., Montine, T. J., Poston, K. L., & Andreasson, K. I.
Venue
Brain
Published
2020-02-17
Volume
143
Issue
3
Pages
932-943
ISSN
  • 0006-8950 (ISSN-L)
  • 1460-2156
OpenAlex
W3006954961
Cited by
99
References
32
FWCI
4.82
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Soluble TREM2 is elevated in Parkinson’s disease subgroups with increased CSF tau. https://app.cochat.ai/papers/10.1093/brain/awaa021
The paper
Wilson, E. N., Swarovski, M. S., Linortner, P., Shahid, M., Zuckerman, A. J., Wang, Q., Channappa, D., Minhas, P. S., Mhatre, S. D., Plowey, E. D., Quinn, J. F., Zabetian, C. P., Tian, L., Longo, F. M., Cholerton, B., Montine, T. J., Poston, K. L., & Andreasson, K. I. (2020). Soluble TREM2 is elevated in Parkinson’s disease subgroups with increased CSF tau. Brain. https://doi.org/10.1093/brain/awaa021

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.